Vertex Pharmaceuticals (VRTX) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Vertex Pharmaceuticals Revenue Highlights


Latest Revenue (Y)

$9.84B

Latest Revenue (Q)

$2.65B

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Vertex Pharmaceuticals Revenue by Period


Vertex Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$9.84B10.17%
2022-12-31$8.93B17.91%
2021-12-31$7.57B22.06%
2020-12-31$6.21B49.07%
2019-12-31$4.16B36.59%
2018-12-31$3.05B22.46%
2017-12-31$2.49B46.20%
2016-12-31$1.70B64.89%
2015-12-31$1.03B77.86%
2014-12-31$580.41M-52.11%
2013-12-31$1.21B-20.63%
2012-12-31$1.53B8.25%
2011-12-31$1.41B883.91%
2010-12-31$143.37M40.49%
2009-12-31$102.05M-41.85%
2008-12-31$175.50M-11.81%
2007-12-31$199.01M-8.02%
2006-12-31$216.36M34.47%
2005-12-31$160.89M56.63%
2004-12-31$102.72M48.56%
2003-12-31$69.14M-57.08%
2002-12-31$161.09M-3.82%
2001-12-31$167.49M114.38%
2000-12-31$78.13M26.83%
1999-12-31$61.60M38.74%
1998-12-31$44.40M1.37%
1997-12-31$43.80M229.32%
1996-12-31$13.30M-39.82%
1995-12-31$22.10M12.76%
1994-12-31$19.60M-29.75%
1993-12-31$27.90M-

Vertex Pharmaceuticals generated $9.84B in revenue during NA 2023, up 10.17% compared to the previous quarter, and up 322.84% compared to the same period a year ago.

Vertex Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30$2.65B-1.55%
2024-03-31$2.69B6.73%
2023-12-31$2.52B1.38%
2023-09-30$2.48B-0.39%
2023-06-30$2.49B4.99%
2023-03-31$2.37B3.13%
2022-12-31$2.30B-1.35%
2022-09-30$2.33B6.29%
2022-06-30$2.20B4.71%
2022-03-31$2.10B1.20%
2021-12-31$2.07B4.46%
2021-09-30$1.98B10.64%
2021-06-30$1.79B4.01%
2021-03-31$1.72B5.93%
2020-12-31$1.63B5.82%
2020-09-30$1.54B0.90%
2020-06-30$1.52B0.62%
2020-03-31$1.52B7.21%
2019-12-31$1.41B48.79%
2019-09-30$949.83M0.91%
2019-06-30$941.29M9.65%
2019-03-31$858.43M-1.34%
2018-12-31$870.11M10.91%
2018-09-30$784.53M4.30%
2018-06-30$752.16M17.38%
2018-03-31$640.80M-1.66%
2017-12-31$651.63M12.71%
2017-09-30$578.16M6.25%
2017-06-30$544.13M-23.87%
2017-03-31$714.72M55.81%
2016-12-31$458.71M10.86%
2016-09-30$413.78M-4.13%
2016-06-30$431.61M8.42%
2016-03-31$398.08M-4.75%
2015-12-31$417.94M34.90%
2015-09-30$309.82M86.55%
2015-06-30$166.08M19.90%
2015-03-31$138.51M-4.18%
2014-12-31$144.56M-19.24%
2014-09-30$178.99M29.31%
2014-06-30$138.42M16.86%
2014-03-31$118.45M-66.27%
2013-12-31$351.16M58.39%
2013-09-30$221.70M-28.66%
2013-06-30$310.75M-5.37%
2013-03-31$328.37M-1.68%
2012-12-31$333.99M-0.60%
2012-09-30$336.01M-19.67%
2012-06-30$418.31M-4.66%
2012-03-31$438.74M-22.12%
2011-12-31$563.34M-14.54%
2011-09-30$659.20M476.10%
2011-06-30$114.42M55.34%
2011-03-31$73.66M12.42%
2010-12-31$65.52M175.37%
2010-09-30$23.80M-24.75%
2010-06-30$31.62M40.99%
2010-03-31$22.43M-33.82%
2009-12-31$33.89M35.79%
2009-09-30$24.96M30.91%
2009-06-30$19.06M-20.50%
2009-03-31$23.98M-26.92%
2008-12-31$32.81M3.80%
2008-09-30$31.61M-54.46%
2008-06-30$69.41M66.55%
2008-03-31$41.67M-

Vertex Pharmaceuticals generated $2.65B in revenue during Q2 2024, up -1.55% compared to the previous quarter, and up 111.40% compared to the same period a year ago.

Vertex Pharmaceuticals Revenue Breakdown


Vertex Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Product$9.87B$4.16B---
ORKAMBI$326.00M$510.70M$771.60M$907.51M$1.33B
KALYDECO$475.50M$553.20M$684.20M$802.87M$991.06M
TRIKAFTA/KAFTRIO$8.94B$7.69B$5.70B$3.86B-
SYMDEKO/SYMKEVI$123.00M$180.00M$420.40M$628.58M$1.42B
Collaborative and Royalty--$1.00M$2.90M$2.10M
TRIKAFTA----$420.11M

Vertex Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (50.00%), TRIKAFTA/KAFTRIO (45.32%), KALYDECO (2.41%), ORKAMBI (1.65%), and SYMDEKO/SYMKEVI (0.62%).

Quarterly Revenue by Product

Product/ServiceJun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
TRIKAFTA/KAFTRIO$2.45B$2.48B$2.33B$2.27B$2.24B$2.10B$2.02B$2.01B$1.89B$1.76B$1.69B$1.56B$1.26B$1.19B$1.09B$960.31M----
ORKAMBI--$44.20M$63.00M$96.30M$122.50M$110.80M$146.20M$121.60M$132.10M$147.38M$184.56M$220.97M$218.70M$215.47M$225.92M$231.98M$234.14M$425.73M$296.71M
KALYDECO--$112.40M$112.80M$125.30M$125.00M$136.10M$139.40M$138.70M$139.00M$152.15M$162.42M$183.29M$186.34M$193.37M$193.87M$203.06M$212.58M$235.58M$249.40M
SYMDEKO/SYMKEVI--$27.80M$33.40M$31.20M$30.60M$34.30M$38.20M$42.70M$64.80M$80.43M$81.42M$133.50M$125.05M$127.51M$156.18M$171.73M$173.16M--
Collaborative and Royalty-----------$900.00K--------
TRIKAFTA----------------$917.72M$895.23M--
Product------------------$1.41B-
SYMDEKO-------------------$403.71M

Vertex Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: TRIKAFTA/KAFTRIO (100.00%).

Vertex Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
Outside the United States$3.83B$3.23B$2.29B$1.38B$1.10B
Other Countries Outside of the United States and Europe$719.80M$525.90M$313.20M$249.94M$214.50M
Europe$3.11B$2.71B$1.97B$1.13B$885.76M
UNITED STATES$6.04B$5.70B$5.29B$4.83B$3.06B

Vertex Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (44.10%), Outside the United States (27.95%), Europe (22.70%), and Other Countries Outside of the United States and Europe (5.25%).

Quarterly Revenue by Country

CountryJun 24Mar 24Dec 23Sep 23Jun 23Mar 23Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Non-US$1.03B$1.17B$929.30M$985.40M$971.00M$878.70M$781.10M$729.30M$601.27M$536.45M$469.87M$313.71M$314.17M$327.52M$239.50M$240.68M$217.33M---
Europe$806.80M$967.40M$735.30M$766.50M$800.00M$807.20M$730.50M$655.50M$632.30M$518.83M$458.91M$404.97M$360.02M$251.37M$257.68M$257.39M$352.95M$184.84M$180.20M$167.75M
Other, Non U.S.$224.50M$203.30M$162.80M$185.40M$163.80M$148.20M$125.60M$97.00M$82.45M$77.54M$64.90M$62.34M$56.49M$70.13M$54.66M$60.48M$49.58M---
UNITED STATES$1.61B$1.52B$1.57B$1.55B$1.51B$1.40B$1.46B$1.42B$1.37B$1.38B$1.26B$1.25B$1.21B$1.22B$1.21B$1.19B$1.01B$710.32M$700.62M$641.10M

Vertex Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (43.90%), Non-US (28.05%), Europe (21.94%), and Other, Non U.S. (6.11%).

Vertex Pharmaceuticals Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
REGNRegeneron Pharmaceuticals$13.12B$3.72B
VRTXVertex Pharmaceuticals$9.84B$2.65B
MRNAModerna$6.85B$241.00M
BNTXBioNTech SE$3.82B$187.60M
BMRNBioMarin Pharmaceutical$2.42B$733.87B
ALNYAlnylam Pharmaceuticals$1.83B$420.15M
SRPTSarepta Therapeutics$1.24B$413.46M
PTCTPTC Therapeutics$937.82M$186.70M
BEAMBeam Therapeutics$377.71M$11.77M
CRSPCRISPR Therapeutics$370.00M$517.00K
DNAGinkgo Bioworks$251.46M$56.21M
KRYSKrystal Biotech$50.70M$83.84M
NTLAIntellia Therapeutics$36.27M$6.96M
CRBUCaribou Biosciences$34.48M$3.46M
VERVVerve Therapeutics$11.76M$5.70M
EDITEditas Medicine-$513.00K
VKTXViking Therapeutics--
MDGLMadrigal Pharmaceuticals-$62.17M

VRTX Revenue FAQ


Vertex Pharmaceuticals's yearly revenue for 2023 was $9.84B, representing an increase of 10.17% compared to 2022. The company's yearly revenue for 2022 was $8.93B, representing an increase of 17.91% compared to 2021. VRTX's yearly revenue for 2021 was $7.57B, representing an increase of 22.06% compared to 2020.

Vertex Pharmaceuticals's quarterly revenue for Q2 2024 was $2.65B, a -1.55% decrease from the previous quarter (Q1 2024), and a 6.11% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $2.69B, a 6.73% increase from the previous quarter (Q4 2023), and a 13.15% increase year-over-year (Q1 2023). VRTX's quarterly revenue for Q4 2023 was $2.52B, a 1.38% increase from the previous quarter (Q3 2023), and a 9.34% increase year-over-year (Q4 2022).

Vertex Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 29.90%, and for the last 5 years (2019-2023) was 136.35%.

Vertex Pharmaceuticals's revenue streams in c 23 are Product, ORKAMBI, KALYDECO, TRIKAFTA/KAFTRIO, and SYMDEKO/SYMKEVI. Product generated $9.87B in revenue, accounting 50.00% of the company's total revenue, up 137.20% year-over-year. ORKAMBI generated $326M in revenue, accounting 1.65% of the company's total revenue, down -36.17% year-over-year. KALYDECO generated $475.5M in revenue, accounting 2.41% of the company's total revenue, down -14.05% year-over-year. TRIKAFTA/KAFTRIO generated $8.94B in revenue, accounting 45.32% of the company's total revenue, up 16.36% year-over-year. SYMDEKO/SYMKEVI generated $123M in revenue, accounting 0.62% of the company's total revenue, down -31.67% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of Vertex Pharmaceuticals was Product. This segment made a revenue of $9.87B, representing 50.00% of the company's total revenue.